Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.9750 (2%) ($11.9750 - $11.9750) on Wed. Dec. 21, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.88% (three month average) | RSI | 47 | Latest Price | $11.9750(2%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.6% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(43%) IWC(42%) IWM(42%) IWN(41%) | Factors Impacting FOLD price | FOLD will decline at least -1.44% in a week (0% probabilities). VXX(-12%) VIXM(-12%) XLU(-10%) ARKG(-9%) TLT(-8%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.44% (StdDev 2.88%) | Hourly BBV | 1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $12.02 | 5 Day Moving Average | $11.96(0.13%) | 10 Day Moving Average | $12.04(-0.54%) | 20 Day Moving Average | $12.02(-0.37%) | To recent high | -5.8% | To recent low | 19.8% | Market Cap | $3.092b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |